Klow Blend (GHK-Cu/KPV/BPC-157/TB500)

The Klow Blend builds upon the Glow Blend formulation (GHK-Cu + BPC-157 + TB-500) with the addition of KPV, a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). This four-peptide combination addresses tissue regeneration through complementary pathways with enhanced anti-inflammatory and antimicrobial capabilities. KPV (Lys-Pro-Val) is the minimal active anti-inflammatory sequence derived from alpha-MSH. Unlike full-length alpha-MSH, KPV does not activate melanocortin receptors involved in pigmentation. Instead, it enters cells and directly inhibits NF-kB activation by preventing the phosphorylation of IkB-alpha and the nuclear translocation of NF-kB p65. This mechanism suppresses the production of a wide array of pro-inflammatory cytokines including IL-1beta, IL-6, IL-8, and TNF-alpha. Luger et al. demonstrated KPV also has direct antimicrobial activity against Staphylococcus aureus and Candida albicans. The four-peptide combination creates a comprehensive tissue-repair system: GHK-Cu drives collagen synthesis and matrix remodeling; BPC-157 promotes angiogenesis through VEGF upregulation; TB-500 accelerates cell migration via actin regulation; and KPV provides potent anti-inflammatory activity through NF-kB suppression plus antimicrobial protection. The addition of KPV is particularly relevant in wound-healing contexts where infection and excessive inflammation are major impediments to repair.

The Klow Blend builds upon the Glow Blend formulation (GHK-Cu + BPC-157 + TB-500) with the addition of KPV, a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). This four-peptide combination addresses tissue regeneration through complementary pathways with enhanced anti-inflammatory and antimicrobial capabilities. KPV (Lys-Pro-Val) is the minimal active anti-inflammatory sequence derived from alpha-MSH. Unlike full-length alpha-MSH, KPV does not activate melanocortin receptors involved in pigmentation. Instead, it enters cells and directly inhibits NF-kB activation by preventing the phosphorylation of IkB-alpha and the nuclear translocation of NF-kB p65. This mechanism suppresses the production of a wide array of pro-inflammatory cytokines including IL-1beta, IL-6, IL-8, and TNF-alpha. Luger et al. demonstrated KPV also has direct antimicrobial activity against Staphylococcus aureus and Candida albicans. The four-peptide combination creates a comprehensive tissue-repair system: GHK-Cu drives collagen synthesis and matrix remodeling; BPC-157 promotes angiogenesis through VEGF upregulation; TB-500 accelerates cell migration via actin regulation; and KPV provides potent anti-inflammatory activity through NF-kB suppression plus antimicrobial protection. The addition of KPV is particularly relevant in wound-healing contexts where infection and excessive inflammation are major impediments to repair.

As a blend, specific ratios vary by formulation. Individual research doses: GHK-Cu at 1-10 micromolar; KPV at 10-100 micromolar in vitro, 0.5-2 mg/kg in animal models; BPC-157 at 10 mcg/kg; TB-500 at 6 mg loading dose in equine studies.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.